High dose rifampicin

DRUG3 trials

Sponsors

University of Cape Town, McGill University Health Centre/Research Institute of the McGill University Health Centre, London School of Hygiene & Tropical Medicine

Conditions

BreastfeedingHIV-1-infectionHIV/AIDS TuberculosisHealthy VolunteerTuberculosis InfectionTuberculosis Meningitis

Phase 1

Pharmacokinetics of Antituberculosis Drugs in Breastfeeding Women

Not yet recruitingNCT07069582

McGill University Health Centre/Research Institute of the McGill University Health CentreBreastfeeding, Healthy Volunteer, Tuberculosis Infection

Start: 2026-04-01End: 2026-10-31Target: 60Updated: 2026-02-10

Phase 2

Linezolid, Aspirin and Enhanced Dose Rifampicin in HIV-TBM

CompletedNCT03927313

University of Cape TownHIV-1-infection, Tuberculosis Meningitis

Start: 2019-06-12End: 2021-03-31Updated: 2021-09-28

Unknown Phase

A randomised controlled trial of 3 strategies for the treatment of ARV naive HIV infected patients with tuberculosis

RecruitingPACTR201105000291300

London School of Hygiene & Tropical MedicineHIV/AIDS Tuberculosis

Start: 2011-05-02Target: 1125Updated: 2026-09-14

Related Papers

Linezolid Population Pharmacokinetic Model in Plasma and Cerebrospinal Fluid Among Patients With Tuberculosis Meningitis

The Journal of Infectious Diseases2023-09-2013 citations

A Phase 2A Trial of the Safety and Tolerability of Increased Dose Rifampicin and Adjunctive Linezolid, With or Without Aspirin, for Human Immunodeficiency Virus–Associated Tuberculous Meningitis: The LASER-TBM Trial

Clinical Infectious Diseases2022-12-0936 citations

A Phase I/II randomized trial of H56:IC31 vaccination and adjunctive cyclooxygenase-2-inhibitor treatment in tuberculosis patients

Nature Communications2021-11-2264 citations

Study protocol for a phase 2A trial of the safety and tolerability of increased dose rifampicin and adjunctive linezolid, with or without aspirin, for HIV-associated tuberculous meningitis [LASER-TBM].

2021-06-0113 citations